Atai Beckley Inc's pre-market stock price gains quickly narrowed from 70% to 30%; Eli Lilly said on Thursday it would acquire psychedelic drug developer AtaiBeckley ATAI.O for up to $3.8 billion, entering the race to develop psychedelic treatments for depression and other mental health disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.